Don't

Give

Up

Annual Report 2010
"That's what I'm going to try to do every minute that I have left. I will thank God for the day and the moment I have. If you see me, smile and give me a hug. That's important to me, too. But try if you can to support . . . so that someone else might survive, might prosper and might actually be cured of this dreaded disease."

–Jim Valvano, 1993 ESPY acceptance speech
Contents

3  Our Story
4  Board of Directors
6  Types of Grants / 2010 Grants Awarded
10  Scientific Advisory Board
12  One Researcher’s Story
13  How to Get Involved
14  Ways to Give
16  Financials
Serving as the heartbeat of The V Foundation for Cancer Research, formed by ESPN and Jim in 1993, his words throughout the ESPY speech have never been more meaningful. After being diagnosed with cancer at the young age of 46, Jim dreamed of finding cures for cancer. Passionate and committed, he wanted to see his fight through to victory. As a former coach, he began to recruit his team of family and friends to lead the Foundation in his quest to eradicate the disease.

As a cancer patient, Jim recognized the need to invest in young physician/scientists to help establish their careers—after all, someone had invested in him early in his career! Addressing the need to help early-career cancer investigators develop into promising future research talents was the first goal of the Foundation. The V Scholar concept was developed in 1994 to address that need. Today, this highly respected award is eagerly sought by young scientists at the nation’s leading cancer centers.

As with any patient, Jim discovered first-hand how slowly science progresses from the lab to the patient’s bedside. He wanted faster solutions, more progress and better answers. Eight years after his death, The V Foundation announced its Translational Research Grants, designed to accelerate laboratory findings with the goal of benefiting patients more quickly.

Although Jim lost his battle with cancer less than two months after delivering the ESPY speech, his dream of a cure lives on through research grants bestowed in his name. The V Foundation has awarded nearly $80 million to more than 100 facilities nationwide.

A relatively young organization, The V Foundation has a strong presence in the scientific community. The Foundation is guided by an elite, all-volunteer Scientific Advisory Board who recommends the research projects funded. This Board is comprised of top physicians and research scientists from prominent universities and cancer centers throughout the country. Working with this team of talented professionals, we are proud to carry out Jim’s vision for the future.

Jim’s dream of finding a cure for cancer is one shared by millions. Although we have not yet achieved this goal, every day we get a little bit closer and will continue to honor his inspiring words, “Don’t Give Up . . . Don’t Ever Give Up!”

—Jim Valvano, former NC State basketball coach and award-winning broadcaster
“The V Foundation grant will allow us to apply for NIH funding, for a program project grant, and also to support more extensive clinical trials after we have done our initial phase one testing.”

*Dr. Kate Matthay, University of California-San Francisco, Parnassus Medical Center*,
*V Designated Grant 2001 and 2008*
*$1.1 million V Foundation investment helped secure*
*$9.7 million in additional funding*
“The V Foundation funding enabled me to recruit talented colleagues into my research program to continue to move our findings to the clinic. Without this funding, this would have been impossible.”

**Dr. Wei Chen, Duke Cancer Institute, V Scholar 2005**

$100,000 V Foundation investment helped secure more than $4 million in additional funding
In 2010 The V Foundation proudly awarded more than $14.2 million in cancer research grants to the following researchers and projects:

**The V Scholar Program**

Designed to identify, retain and advance the careers of talented young investigators. This grant provides funds directly to young scientists to establish their own independent laboratory and gain the competitive edge necessary to earn additional funding from other sources. The V Scholars determine how to best use the funds in their research projects. This grant is for a $200,000, two-year commitment.

**V Scholars**

**Srinivasan Yegnasubramanian, M.D., Ph.D.**  
*Sidney Kimmel Cancer Center at Johns Hopkins*  
Baltimore, MD  
*Martin D. Abeloff, M.D. V Scholar Award*  
Pre-clinical Developmental Clinical Testing of DNA Methylation Biomarkers of Aggressive Prostate Cancer

**André Hoelz, Ph.D.**  
*California Institute of Technology*  
Pasadena, CA  
*Albert Wyrick V Scholar Award*  
Structural and Functional Analysis of Macromolecular Machines in Chromatin Biology and Carcinogenesis Funded by Michael and Carole Marks

**Yong Cang, Ph.D.**  
*Sanford-Burnham Medical Research Institute*  
La Jolla, CA  
Investigation of Hepatocarcinogenesis Using a Novel Mouse Model

**Mark Chiang, M.D., Ph.D.**  
*University of Michigan Comprehensive Cancer Center*  
Ann Arbor, MI  
The Significance of Tlx1/Hox11 in T-cell Acute Lymphoblastic Leukemia/lymphoma

**Benjamin Deneen, Ph.D.**  
*Baylor College of Medicine*  
*Dan L. Duncan Cancer Center*  
Houston, TX  
Delineating the Role of Nuclear Factor I-A in the Generation of Glioblastoma Multiforme: Linking Glial Fate Determination and Tumorigenesis

**Danica Galonic Fujimori, Ph.D.**  
*The Helen Diller Family Comprehensive Cancer Center*  
*University of California, San Francisco*  
San Francisco, CA  
Targeting Epigenetic Mechanisms of Cancer: Elucidating Roles of Jumonji Histone-Demethylasas

**Monica Gostissa, Ph.D.**  
*Boston Children’s Hospital*  
Boston, MA  
Elucidating Principles of Chromosomal Translocations in B Cells

**Monica L. Guzman, Ph.D.**  
*Weill Cornell Medical College*  
New York, NY  
Transcriptional and Epigenetic Characterization of the Drug Resistance in Acute Myelogenous Leukemia Stem Cells

**M. Kyle Hadden, Ph.D.**  
*Carole and Ray Neag Comprehensive Cancer Center*  
*University of Connecticut*  
Farmington, CT  
A Chemical Biology Approach to Understanding the Anti-Cancer Effects of Vitamin D3
Hui Li, Ph.D.
University of Virginia Health System
Charlottesville, VA
Role of RNA Trans-splicing in Prostate Cancer
Funded by Delta Chi Fraternity

Don X. Nguyen, Ph.D.
Yale Cancer Center
New Haven, CT
Tumor-microenvironment Interactions that Regulate the Therapeutic Response of Lung Cancer Brain Metastasis
Funded in memory of Christopher T. Carroll

Vu H. Nguyen, M.D.
The University of Chicago Comprehensive Cancer Center
Chicago, IL
Preserving Tumor Immunity Following Hematopoietic Stem Cell Transplantation

Ken-ichi Noma, Ph.D.
The Wistar Institute
Philadelphia, PA
Identification of a Novel Pathway that Facilitates Chromosome Instability in Cancer

Jennifer Rhodes, Ph.D.
Fox Chase Cancer Center
Philadelphia, PA
Dissecting the Oncogenic and Molecular Function of a Novel Hematopoietic Zinc Finger Factor

Jorge Torres, Ph.D.
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, CA
Functional Proteomics in Cell Division and Cancer Therapy

Hushan Yang, Ph.D.
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, PA
Predisposition to Hepatocellular Carcinoma in HBV Patients – A Multigenic Approach to MicroRNA

Jing Zhang, Ph.D.
Carbone Cancer Center
University of Wisconsin
Madison, WI
The Role of Endogenous Kras and Nras Signaling in Myeloid Leukemias

The Designated Grant Program

Funds projects in communities or regions local to the fundraising area. Supporters and donors work with the Foundation to identify a specific cancer, facility or awareness program. The Partners in Excellence grant program and the SPORE Supplement (Specialized Program of Research Excellence) grant program are examples of designated grants.

Designated Grants

William Janssen, Ph.D.
Shari Pilon-Thomas, Ph.D.
James J. Mulé, Ph.D.
H. Lee Moffitt Cancer Center
Tampa, FL
Combined Cell Therapy Approach to the Treatment of Neuroblastoma
Funded by 2010 Dick Vitale Gala

Erwin G. Van Meir, Ph.D.
Winship Cancer Institute of Emory University
Atlanta, GA
Accelerating the Translation Of Novel Small Molecule HIF Inhibitors to Cancer Patient Treatment

Leisha A. Emens, M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Facilitating Potent Breast Tumor Immunity by Antibody-Enhanced Vaccination
Funded by Kay Yow/WBCA Foundation
Kentucky Prostate Cancer Coalition
Louisville, KY
Funded by Louisville Friends of V

MD Anderson Cancer Center
Bast/Goodfellow Physician Scientist Endowment
Houston, TX
Funded by the Tamar Chotzen Goodfellow Research Fund
In Honor of Dr. Robert C. Bast, Jr.

Steven M. Zeitels, M.D., FACS
Massachusetts General Hospital
Boston, MA
Voice Preservation in the Treatment of Early Glottic (Laryngeal) Cancer
Funded by the 2010 Dick Vitale Gala

Nancy E. Thomas, M.D., Ph.D.
David W. Ollila, M.D.
UNC Lineberger Cancer Center
Chapel Hill, NC
Tumor DNA-Methylation as a Biomarker for Melanoma
Funded by Jimmy V Celebrity Golf Classic
In Honor of Richard Hopkins and Parker Ellison

Shands Children’s Hospital
University of Florida
Pediatric Bone Marrow Unit
Gainesville, FL

Rajeshwar Rao Tekmal, Ph.D.
University of Texas Health Science Center at San Antonio
San Antonio, TX
Novel Therapeutic Approach to Overcome Resistance to Endocrine Therapies of Breast Cancer
Funded by the Kay Yow/WBCA Foundation

Gregory Hale, M.D.
All Children’s Hospital
St. Petersburg, FL
Cellular Therapies to Treat Children and Adolescents with Refractory Malignancies
Funded by the 2010 Dick Vitale Gala

James M. Ford, M.D.
Stanford University Medical Center
Palo Alto, CA
Gastric Cancer Genetics Research
Funded by the Gastric Cancer Fund

St. Helena Hospital
St. Helena, CA
Caring for the Future Campaign
Funded by The V Foundation Wine Celebration

A. Thomas Look, M.D.
Dana-Farber Cancer Institute
Boston, MA
Pathway Addiction Due to Autocrine Activation of MET Provides a New Therapeutic Target in AML
Funded by The V Foundation Wine Celebration
In Honor of Teri Kuhn

The Translational Research Grant Program
Facilitate the transition of projects from the laboratory to the clinic. Basic scientists and clinicians seek to apply fundamental knowledge of cancer and bring the benefits of the new basic-level understandings to patients more quickly and efficiently through a seamless collaboration. This grant is for a $600,000, three-year commitment.

Translational Grants
Mark Alan Rosen, M.D., Ph.D.
William Lee, M.D., Ph.D.
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Use of PET and MR Imaging Biomarkers to Predict Response of Renal Cell Carcinoma to Tyrosine Kinase Inhibitor Therapy
Cory T. Abate-Shen, Ph.D.
Edward Gelmann, M.D.
Herbert Irving Comprehensive Cancer Center
Columbia University
New York, NY
Pre-clinical and Clinical Approaches for Developing New Treatments for Castration-resistant Prostate Cancer

A. Craig Lockhart, M.D.
Siteman Cancer Center
Washington University
St. Louis, MO
Whole Genome Sequencing to Identify Predictive Markers and Novel Therapeutic Targets in Gastric and Gastroesophageal Cancers

Amir Goldkorn, M.D.
Parkash Gill, M.D.
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Targeting the Ephrin Pathway: A Phase 1 Therapeutic Trial with Circulating Tumor Cell Molecular Correlates

Garrett M. Brodeur, M.D.
Robert J. Levy, M.D.
Children’s Hospital of Philadelphia Research Institute
Philadelphia, PA
Nanoparticle Delivery of TRK Inhibitors in Neuroblastomas

Nancy Lin, M.D.
Kornelia Polyak, M.D., Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Targeting the Il-6/Jak2/Stat3 Pathway in Human Breast Cancer

Christopher E. Touloukian, M.D.
Simon Cancer Center, Indiana University
Indianapolis, IN
The Use of Gene-modified Lymphoid Progenitor Cells for Treatment of Patients with Metastatic Melanoma Funded by The V Foundation Wine Celebration In Honor of Blakesley and Cyril Chappellet

Derek C. Radisky, Ph.D.
Lynn Hartmann, M.D.
Mayo Clinic Cancer Center
Jacksonville, FL
Lobular Involution and Breast Cancer in Postmenopausal Women

Ignacio I. Wistuba, M.D.
Edward Kim, M.D.
MD Anderson Cancer Center
University of Texas
Houston, TX
The Identification of Biomarkers for Predicting Response to Treatment in Advanced Non-Small Cell Lung Cancer

“The V Foundation was instrumental in my development and the development of my whole career. They supported me at the earliest time of my scientific and medical research career. It was when I was first beginning as an investigator, in the mid-1990s, and The V Foundation supported this research at a time where the federal government wasn’t quite ready to. The V Foundation provided the seed [money] for all the research, and quite frankly allowed us to get to the point where we are now, to be able to help women at risk of cancer.”

Dr. Powel Brown, MD Anderson Cancer Center, V Scholar 1996
$100,000 V Foundation investment helped secure nearly $10 million in additional funding
Although The V Foundation has a very small staff, we are led by some of the biggest names in the scientific community. The V Foundation’s Scientific Advisory Board, comprised of illustrious physicians and research scientists at the nation’s most prominent cancer centers and universities, is an all-volunteer group that ensures all grant proposals meet the highest scientific merit.

Robert C. Bast, Jr., M.D.
Vice President for Translational Research
MD Anderson Cancer Center
Houston, TX

William T. Beck, Ph.D.
Professor and Head
Department of Biopharmaceutical Sciences
University of Illinois at Chicago
Chicago, IL

Gerold Bepler, M.D., Ph.D.
President and CEO
Karmanos Cancer Institute
Detroit, MI

Nancy E. Davidson, M.D.
Director
University of Pittsburgh Cancer Institute
Pittsburgh, PA

H. Shelton Earp III, M.D.
Director & Lineberger Professor
Professor of Medicine and Pharmacology
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Paul F. Engstrom, M.D.
Senior Vice President for Population Science
Fox Chase Cancer Center
Philadelphia, PA

Olivera J. Finn, Ph.D.
Professor & Chair, Dept. of Immunology
University of Pittsburgh School of Medicine
Pittsburgh, PA

Richard I. Fisher, M.D.
Samuel E. Durand Professor of Medicine
Director, University of Rochester Medical Faculty Group
Director, James P. Wilmot Cancer Center
University of Rochester Medical Center
Rochester, NY

James M. Ford, M.D.
Associate Professor of Medicine and Genetics
Stanford University School of Medicine
Stanford, CA

Lynn M. Matrisian, Ph.D.
Professor and Chair, Department of Cancer Biology
Vanderbilt-Ingram Cancer Center
Nashville, TN

John D. Minna, M.D.
Professor and Director, Hamon Center for Therapeutic Oncology Research
Professor, Internal Medicine & Pharmacology
Director, Center for Cancer Genetics
University of Texas Southwestern Medical Center
Dallas, TX
This expert Board recommends funding for the most promising research projects through its comprehensive knowledge base. All members of the Scientific Advisory Board have made outstanding contributions in their respective fields, and we are proud to have their involvement on our behalf.

**Joseph O. Moore, M.D.**  
*Medical Director*  
Duke Raleigh Cancer Center  
Professor, Hematology Oncology  
Duke Cancer Institute  
Durham, NC

**William G. Nelson, M.D., Ph.D.**  
*Professor, Oncology and Urology*  
*Director*  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
Baltimore, MD

**Brian Patrick O’Neill, M.D.**  
*Professor of Neurology, Mayo Clinic College of Medicine*  
*Leader, Translational Research Program in Neuro-Oncology*  
*Director, Mayo SPORE in Brain Cancer*  
Mayo Clinic Cancer Center  
Rochester, MN

**Richard O’Reilly, M.D.**  
*Chair, Department of Pediatrics*  
*Chief, Pediatric Bone Marrow Transplant Services*  
Memorial Sloan-Kettering Cancer Center  
New York, NY

**Jerome Ritz, M.D.**  
*Professor of Medicine, Harvard Medical School*  
Dana-Farber Cancer Institute  
Boston, MA

**David E. Schuller, M.D.**  
*Vice President, Medical Center Expansion and Outreach*  
CEO Emeritus, James Cancer Hospital & Solove Research Institute  
The Ohio State University  
Columbus, OH

**Jonathan W. Simons, M.D.**  
*Chief Executive Officer*  
Prostate Cancer Foundation  
Santa Monica, CA

**Margaret A. Tempero, M.D.**  
*Chief, Medical Oncology*  
Department of Medicine  
University of California at San Francisco  
San Francisco, CA

**Daniel D. Von Hoff, M.D., F.A.C.P.**  
*Physician-in-Chief and Distinguished Professor*  
Translational Genomics Research Institute  
Phoenix, AZ

**Martin D. Abeloff, M.D.**  
*In Memoriam*
In 2007, James Mulé, Ph.D. from H. Lee Moffitt Cancer Center received a $1 million V Foundation Designated Grant to support studies that will allow scientists to explore a number of immune-based therapies to treat melanoma, including the use of tumor vaccines.

Skin cancer is the most common of all cancer types. More than one million skin cancers are diagnosed each year in the U.S. That is more than cancers of the prostate, breast, lung, colon, uterus, ovaries and pancreas combined. While the incidence of many other cancers has been on the decline for the past few decades, the number of skin cancer cases has continued to rise.

Dr. Mulé is leading a team of skin cancer researchers at Moffitt. His clinical research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. In fact, Dr. Mulé has developed a “V” Vaccine to aid melanoma patients.

"We are no longer restrained by what Mother Nature has given us," said Dr. Mulé. "In melanoma patients [the vaccine] creates new, functioning lymph nodes in the body. We believe the “V” vaccine will set the stage for creating ‘designer’ lymph nodes to effectively boost immunity to a variety of cancer types." This vaccine is now going into clinical trials.

Dr. Mulé has significantly leveraged his V Foundation grant:

- NCI grant for approximately $2 million
- NCI grant for approximately $2.1 million
- Miriam and Sheldon Adelson Research Foundation grant for $500,000
- Funding request for a second clinical trial is being submitted to the NCI

Dr. Mulé has published nearly 200 articles on vaccines and other approaches to stimulate the immune system to fight cancer. He has appeared on ABC World News Tonight with the late Peter Jennings.
How to Get Involved

We would not be where we are today without the continued support of people like you. Through your involvement, you have helped the Foundation grow and enabled us to continue to increase the rate at which we fund cancer research.

There are numerous ways to get involved and support The V Foundation throughout the year.

Become a fan of our Facebook page and follow us on Twitter and YouTube. In the age of social media, this is a great way to keep up with the latest V Foundation news and see what’s happening at a given time.

Sign up for our electronic newsletter. Once a month, you will receive The V Foundation’s latest news updates, information on upcoming events and other relevant information. Visit jimmyv.org to subscribe.

Host a Community Event. Community events are a great way to get people involved and spread awareness about our cause. Donations from community events go directly to cancer research.

Share Your Story of an experience with cancer or how you’ve been inspired to do something to fight this disease. We want to hear from you. Visit jimmyv.org/share-your-story.html.

Everyone’s got a story to tell. If you’ve overcome cancer, have an inspirational story to share or know someone who has, we want to hear from you.

Donations are undoubtedly a wonderful way for friends of The V Foundation to support our cause, as 100 percent of all donations go directly to fund cancer research (operating expenses are paid by our endowment fund.) Donating on jimmyv.org is perhaps the easiest way to get involved.

Join The V Foundation online!

facebook.com/vfoundation
twitter.com/thefoundation
youtube.com/thefoundation
jimmyv.org/blog

More than $100 million raised, funding 100+ cancer centers nationwide.
We need your help. I need your help. We need money for research. It may not save my life. It may save my children’s lives. It may save someone you love.

—Jim Valvano

Those memorable words spoken by Jim Valvano symbolize the work of The V Foundation for Cancer Research. Since 1993, people from all walks of life have joined our cause.

Your donations will advance cancer research initiatives and lead to new discoveries and treatments for cancer.

For more information on how you can help, please contact John Leshney, Senior Vice President of Development, at 1-800-4JIMMYV (800-454-6698 / 919-380-9505) or jleshney@jimmyv.org.

Thank you in advance for your support.

Remember The V Foundation in Your Will or Trust

Support The V Foundation after providing for your family and loved ones. Bequests and trusts using cash, securities, and property strengthen our research and provide financial stability.

Gifts of Securities and Assets

Gifts of appreciated stock, mutual fund shares or other securities not only benefit The V Foundation, but also may provide a significant tax savings for you. Gifts of real estate, paid-up life insurance policies, or tangible personal property are innovative ways to make an impact.

Tribute Gifts

A gift in memory of a loved one, or in honor of a special friend or family member is a thoughtful way to express your appreciation and support. The V Foundation will send a special acknowledgement on your behalf to the person of your choosing.

Endowment Gifts

The V Foundation’s endowment fund has made a tremendous impact on our cause. Your gift to the endowment can too. The fund’s earnings enable us to pay all Foundation operating expenses, thereby allowing 100% of every dollar contributed to go directly to cancer research, as well as ensure the future of The V Foundation. Giving to our endowment multiplies our abilities to fund cancer research now and in the future.
### STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS

**For the Years Ended September 30, 2010 and 2009**

<table>
<thead>
<tr>
<th></th>
<th>UNRESTRICTED</th>
<th>TEMPORARILY REstricted</th>
<th>PERMANENTLY RESTRICTED</th>
<th>TOTAL</th>
<th>2009</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues, gains and other support</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>7,183,962</td>
<td>746,276</td>
<td>753,423</td>
<td>8,683,661</td>
<td>10,114,129</td>
</tr>
<tr>
<td>Special events, net of expenses</td>
<td>2,116,174</td>
<td></td>
<td></td>
<td>2,116,174</td>
<td>2,043,272</td>
</tr>
<tr>
<td>Investment income, net of expenses</td>
<td>369,272</td>
<td></td>
<td></td>
<td>369,272</td>
<td>466,032</td>
</tr>
<tr>
<td>Net realized and unrealized gains on investments designated for long-term use</td>
<td>1,345,115</td>
<td></td>
<td></td>
<td>1,345,115</td>
<td>822,180</td>
</tr>
<tr>
<td><strong>Net assets released from restrictions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfaction of program restrictions</td>
<td>7,562,159</td>
<td>(2,512,159)</td>
<td>(5,050,000)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>TOTAL REVENUES, GAINS, AND OTHER SUPPORT</strong></td>
<td>18,576,682</td>
<td>(1,765,883)</td>
<td>(4,296,577)</td>
<td>12,514,222</td>
<td>13,445,613</td>
</tr>
</tbody>
</table>

### Expenses

|                      | 2010         | 2009         |               |             |            |
|----------------------|--------------|--------------|---------------|-------------|
| Program              | 12,414,329   |              |               | 12,414,329  | 12,577,850 |
| Management and general | 376,633     |              |               | 376,633     | 322,354    |
| Fundraising          | 445,497      |              |               | 445,497     | 429,690    |
| **TOTAL EXPENSES**   | 13,236,459   |              |               | 13,236,459  | 13,329,894 |

|                      |              | (1,765,883)  | (4,296,577)  | (722,237)   | 115,719    |
| Changes in net assets |              |              |              |             |            |
| Net assets, beginning of year | (2,565,877) | 1,765,883    | 17,574,814   | 16,774,820  | 16,659,101 |
| **NET ASSETS, END OF YEAR** | $2,774,346   |              |              | $16,052,583 | $16,774,820 |

### STATEMENTS OF FINANCIAL POSITION

**September 30, 2010 and 2009**

|                      | 2010         | 2009         |               |             |            |
|----------------------|--------------|--------------|---------------|-------------|
| **ASSETS**           |              |              |               |             |            |
| **Current assets**   |              |              |               |             |            |
| Cash and cash equivalents | $11,504,753 | $11,011,434  |               |             |            |
| Certificates of deposit | 1,515,920   | 2,627,141    |               |             |            |
| Pledges receivable, net of allowance | 1,430,492   | 2,214,078    |               |             |            |
| Accounts receivable  | 63,000       | 596,250      |               |             |            |
| Other current assets | 38,983       | 44,315       |               |             |            |
| **TOTAL CURRENT ASSETS** | 14,553,148   | 16,493,218   |               |             |            |
| **Long-term assets** |              |              |               |             |            |
| Pledge receivables    |              |              |               |             |            |
| net of allowance      | 1,933,720    | 2,966,695    |               |             |            |
| Investments designated for long-term use | 18,742,971 | 16,857,023   |               |             |            |
| Property and equipment, net | 10,743     | 10,607       |               |             |            |
| Intangible assets - finite-lived, net of amortization | 236       | 410          |               |             |            |
| **TOTAL OTHER ASSETS** | 20,687,670   | 19,834,735   |               |             |            |
| **TOTAL ASSETS**      | $35,240,818  | $36,327,953  |               |             |            |

<p>|                      | 2010         | 2009         |               |             |            |
| <strong>LIABILITIES AND NET ASSETS</strong> |              |              |               |             |            |
| <strong>Current liabilities</strong> |              |              |               |             |            |
| Accounts payable and accrued expenses | $60,860     | $13,014      |               |             |            |
| Grants payable        | 10,011,666   | 10,161,417   |               |             |            |
| <strong>TOTAL CURRENT LIABILITIES</strong> | 10,072,526   | 10,174,431   |               |             |            |
| <strong>Long-term liabilities</strong> |              |              |               |             |            |
| Grants payable        | 9,115,709    | 9,378,702    |               |             |            |
| <strong>TOTAL LIABILITIES</strong> | 19,188,235   | 19,533,133   |               |             |            |
| <strong>Net assets</strong>        |              |              |               |             |            |
| Unrestricted          | 2,774,346    | (2,565,877)  |               |             |            |
| Temporarily restricted | —           | 1,765,883    |               |             |            |
| Permanently restricted | 13,278,237  | 17,574,814   |               |             |            |
| <strong>TOTAL NET ASSETS</strong>  | 16,052,583   | 16,774,820   |               |             |            |
| <strong>TOTAL LIABILITIES AND NET ASSETS</strong> | $35,240,818  | $36,327,953  |               |             |            |</p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>V Scholar</td>
<td>17</td>
</tr>
<tr>
<td>Translational</td>
<td>9</td>
</tr>
<tr>
<td>Designated</td>
<td>12</td>
</tr>
<tr>
<td>SPORE Supplement</td>
<td>1</td>
</tr>
<tr>
<td>Total of All Grants</td>
<td>39</td>
</tr>
</tbody>
</table>

**GRANTS AWARDED, BY TYPE**

<table>
<thead>
<tr>
<th>Category</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ohio</td>
<td>$3,252,017</td>
</tr>
<tr>
<td>Tennessee</td>
<td>$2,200,000</td>
</tr>
<tr>
<td>Illinois</td>
<td>$2,105,750</td>
</tr>
<tr>
<td>Indiana</td>
<td>$1,429,175</td>
</tr>
<tr>
<td>Minnesota</td>
<td>$1,004,322</td>
</tr>
<tr>
<td>Virginia</td>
<td>$2,002,650</td>
</tr>
<tr>
<td>Georgia</td>
<td>$1,012,986</td>
</tr>
<tr>
<td>North Carolina</td>
<td>$8,840,954</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>$7,400,000</td>
</tr>
<tr>
<td>Florida</td>
<td>$5,661,860</td>
</tr>
<tr>
<td>New York</td>
<td>$4,979,861</td>
</tr>
<tr>
<td>Texas</td>
<td>$5,869,697</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>$4,606,709</td>
</tr>
<tr>
<td>New York</td>
<td>$4,311,200</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>$2,200,000</td>
</tr>
</tbody>
</table>

**TOP 15 GRANTS DISTRIBUTIONS BY STATE**

<table>
<thead>
<tr>
<th>State</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>$16,585,362</td>
</tr>
<tr>
<td>North Carolina</td>
<td>$8,840,954</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>$7,400,000</td>
</tr>
<tr>
<td>Texas</td>
<td>$5,869,697</td>
</tr>
<tr>
<td>Florida</td>
<td>$5,661,860</td>
</tr>
<tr>
<td>New York</td>
<td>$4,979,861</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>$4,606,709</td>
</tr>
<tr>
<td>Maryland</td>
<td>$4,311,200</td>
</tr>
<tr>
<td>Ohio</td>
<td>$3,252,017</td>
</tr>
<tr>
<td>Tennessee</td>
<td>$2,200,000</td>
</tr>
<tr>
<td>Illinois</td>
<td>$2,105,750</td>
</tr>
<tr>
<td>Indiana</td>
<td>$1,429,175</td>
</tr>
<tr>
<td>Virginia</td>
<td>$2,002,650</td>
</tr>
<tr>
<td>Georgia</td>
<td>$1,012,986</td>
</tr>
<tr>
<td>Minnesota</td>
<td>$1,004,322</td>
</tr>
</tbody>
</table>

**GRANT DISTRIBUTIONS BY CANCER SITE**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gynecological</td>
<td>$100,000</td>
</tr>
<tr>
<td>Thyroid</td>
<td>$250,000</td>
</tr>
<tr>
<td>Cervical/Ovarian</td>
<td>$550,000</td>
</tr>
<tr>
<td>Ewings</td>
<td>$775,000</td>
</tr>
<tr>
<td>GU Renal</td>
<td>$1,850,000</td>
</tr>
<tr>
<td>Myeloma</td>
<td>$500,000</td>
</tr>
<tr>
<td>GI</td>
<td>$1,397,612</td>
</tr>
<tr>
<td>Brain</td>
<td>$1,650,000</td>
</tr>
<tr>
<td>Melanoma</td>
<td>$4,450,000</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>$4,850,000</td>
</tr>
<tr>
<td>Colon</td>
<td>$2,200,000</td>
</tr>
<tr>
<td>Prostate</td>
<td>$3,360,000</td>
</tr>
<tr>
<td>Lung</td>
<td>$7,600,000</td>
</tr>
<tr>
<td>Pediatric</td>
<td>$8,314,000</td>
</tr>
<tr>
<td>Breast</td>
<td>$9,270,000</td>
</tr>
<tr>
<td>Leukemia/Lymphoma</td>
<td>$10,775,000</td>
</tr>
<tr>
<td>General Cancer</td>
<td>$20,161,992</td>
</tr>
<tr>
<td>Total</td>
<td>$78,053,604</td>
</tr>
</tbody>
</table>

**GRANTS AWARDED, BY TYPE**

<table>
<thead>
<tr>
<th>Category</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>V Scholar</td>
<td>17</td>
</tr>
<tr>
<td>Translational</td>
<td>9</td>
</tr>
<tr>
<td>Designated</td>
<td>12</td>
</tr>
<tr>
<td>SPORE Supplement</td>
<td>1</td>
</tr>
<tr>
<td>Total of All Grants</td>
<td>39</td>
</tr>
</tbody>
</table>

**TOP 15 GRANTS DISTRIBUTIONS BY STATE**

<table>
<thead>
<tr>
<th>State</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>$16,585,362</td>
</tr>
<tr>
<td>North Carolina</td>
<td>$8,840,954</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>$7,400,000</td>
</tr>
<tr>
<td>Texas</td>
<td>$5,869,697</td>
</tr>
<tr>
<td>Florida</td>
<td>$5,661,860</td>
</tr>
<tr>
<td>New York</td>
<td>$4,979,861</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>$4,606,709</td>
</tr>
<tr>
<td>Maryland</td>
<td>$4,311,200</td>
</tr>
<tr>
<td>Ohio</td>
<td>$3,252,017</td>
</tr>
<tr>
<td>Tennessee</td>
<td>$2,200,000</td>
</tr>
<tr>
<td>Illinois</td>
<td>$2,105,750</td>
</tr>
<tr>
<td>Indiana</td>
<td>$1,429,175</td>
</tr>
<tr>
<td>Virginia</td>
<td>$2,002,650</td>
</tr>
<tr>
<td>Georgia</td>
<td>$1,012,986</td>
</tr>
<tr>
<td>Minnesota</td>
<td>$1,004,322</td>
</tr>
</tbody>
</table>

**GRANT DISTRIBUTIONS BY CANCER SITE**

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Total Grants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gynecological</td>
<td>$100,000</td>
</tr>
<tr>
<td>Thyroid</td>
<td>$250,000</td>
</tr>
<tr>
<td>Cervical/Ovarian</td>
<td>$550,000</td>
</tr>
<tr>
<td>Ewings</td>
<td>$775,000</td>
</tr>
<tr>
<td>GU Renal</td>
<td>$1,850,000</td>
</tr>
<tr>
<td>Myeloma</td>
<td>$500,000</td>
</tr>
<tr>
<td>GI</td>
<td>$1,397,612</td>
</tr>
<tr>
<td>Brain</td>
<td>$1,650,000</td>
</tr>
<tr>
<td>Melanoma</td>
<td>$4,450,000</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>$4,850,000</td>
</tr>
<tr>
<td>Colon</td>
<td>$2,200,000</td>
</tr>
<tr>
<td>Prostate</td>
<td>$3,360,000</td>
</tr>
<tr>
<td>Lung</td>
<td>$7,600,000</td>
</tr>
<tr>
<td>Pediatric</td>
<td>$8,314,000</td>
</tr>
<tr>
<td>Breast</td>
<td>$9,270,000</td>
</tr>
<tr>
<td>Leukemia/Lymphoma</td>
<td>$10,775,000</td>
</tr>
<tr>
<td>General Cancer</td>
<td>$20,161,992</td>
</tr>
<tr>
<td>Total</td>
<td>$78,053,604</td>
</tr>
</tbody>
</table>